Demographic, disease, and transplant-related characteristics of children receiving BMT for hematologic malignancy from 1990 to 2007 by BMI categories
| N = 3687 . | UW N (%) . | RUW N (%) . | Normal N (%) . | OW N (%) . | OB N (%) . |
|---|---|---|---|---|---|
| Patients | 282 (7) | 509 (14) | 1880 (51) | 573 (15) | 443 (12) |
| Age median (range), years | 13 (2-18) | 12 (2-18) | 11 (2-18) | 10 (2-18) | 10 (2-18) |
| Age groups | |||||
| 2-5 | 39 (14) | 80 (16) | 339 (18) | 115 (20) | 96 (22) |
| 6-9 | 55 (20) | 112 (22) | 450 (24) | 156 (27) | 120 (27) |
| 10-13 | 54 (19) | 111 (22) | 394 (21) | 124 (22) | 115 (26) |
| 14-18 | 134 (48) | 206 (40) | 697 (37) | 178 (31) | 112 (25) |
| Sex | |||||
| Male | 195 (69) | 319 (63) | 1067 (57) | 339 (59) | 286 (65) |
| Ethnicity/race | |||||
| White | 149 (53) | 329 (65) | 1321 (70) | 410 (72) | 314 (71) |
| African American | 9 (3) | 20 (4) | 83 (4) | 30 (5) | 28 (6) |
| Hispanic | 4 (1) | 11 (2) | 82 (4) | 37 (6) | 21 (5) |
| Asian | 33 (12) | 48 (9) | 151 (8) | 36 (6) | 21 (5) |
| Middle eastern | 65 (23) | 74 (15) | 141 (8) | 26 (5) | 23 (5) |
| Missing | 20 (7) | 26 (4) | 91 (4) | 31 (5) | 31 (6) |
| Patient region | |||||
| United States | 64 (23) | 174 (34) | 828 (44) | 309 (54) | 270 (61) |
| Canada | 6 (2) | 17 (3) | 85 (5) | 26 (5) | 20 (5) |
| Europe | 74 (26) | 126 (25) | 510 (27) | 127 (22) | 84 (19) |
| Asia | 32 (11) | 37 (7) | 112 (6) | 27 (5) | 16 (4) |
| Middle East | 73 (26) | 82 (16) | 136 (7) | 28 (5) | 17 (4) |
| Lansky score | |||||
| ≥90% | 233 (83) | 422 (83) | 1579 (84) | 490 (86) | 377 (85) |
| Disease and status | |||||
| AML CR1 | 82 (32) | 108 (24) | 419 (25) | 82 (16) | 56 (14) |
| AML CR2 | 21 (8) | 55 (12) | 168 (10) | 52 (10) | 39 (9) |
| MDS | 27 (10) | 62 (12) | 170 (9) | 51 (9) | 31 (7) |
| ALL CR1 | 48 (19) | 79 (18) | 265 (32) | 82 (16) | 56 (14) |
| ALL CR2 | 48 (19) | 115 (26) | 549 (32) | 230 (44) | 203 (49) |
| CML early | 39 (15) | 71 (16) | 248 (15) | 63 (12) | 48 (12) |
| CML inter/adv | 17 (7) | 18 (18) | 59 (3) | 12 (2) | 10 (1) |
| Time dx to BMT-n | |||||
| <12 months | 193 (68) | 305 (60) | 1051 (56) | 274 (48) | 179 (40) |
| >12 months | 88 (31) | 203 (40) | 829 (44) | 299 (52) | 264 (60) |
| HLA match/donor | |||||
| HLA Id siblings | 182 (65) | 269 (53) | 829 (44) | 241 (42) | 153 (35) |
| Other related patients | 24 (9) | 46 (9) | 158 (8) | 51 (9) | 43 (10) |
| URD well matched | 16 (6) | 44 (9) | 187 (10) | 78 (14) | 70 (16) |
| URD partially matched | 45 (16) | 111 (22) | 541 (29) | 153 (27) | 120 (27) |
| URD mismatched | 15 (5) | 39 (8) | 165 (9) | 50 (9) | 57 (13) |
| Conditioning | |||||
| CY +TBI+/−others | 158 (6) | 308 (12) | 992 (40) | 704 (28) | 331 (13) |
| BU + CY+/−others | 124 (10) | 201 (17) | 475 (40) | 282 (24) | 112 (9) |
| ATG or Campath | |||||
| ATG | 13 (5) | 32 (6) | 130 (7) | 45 (8) | 39 (9) |
| Campath | 4 (1) | 9 (2) | 42 (2) | 16 (3) | 6 (1) |
| TNC/kg- median 3 × 108/kg | |||||
| <3 | 129 (46) | 225 (44) | 877 (47) | 308 (54) | 251 (57) |
| >3 | 136 (48) | 249 (49) | 854 (45) | 239 (42) | 171 (39) |
| Unknown | 17 (6) | 35 (7) | 149 (8) | 26 (5) | 21 (5) |
| GVHD prophylaxis | |||||
| CSA + MTX+/− other | 203 (72) | 371 (73) | 1312 (70) | 404 (71) | 292 (66) |
| CSA only | 31 (11) | 54 (11) | 162 (9) | 51 (9) | 38 (9) |
| T depletion | 48 (17) | 84 (17) | 406 (22) | 118 (21) | 113 (26) |
| Year of transplant | |||||
| 1990-1998 | 190 (67) | 327 (65) | 1250 (66) | 335 (58) | 273 (61) |
| 1999-2007 | 92 (33) | 182 (35) | 630 (34) | 238 (42) | 170 (39) |
| Follow-up | |||||
| Median, range, months | 99 (3-221) | 87 (3-222) | 85 (3-229) | 80 (3-220) | 86 (3-201) |
| N = 3687 . | UW N (%) . | RUW N (%) . | Normal N (%) . | OW N (%) . | OB N (%) . |
|---|---|---|---|---|---|
| Patients | 282 (7) | 509 (14) | 1880 (51) | 573 (15) | 443 (12) |
| Age median (range), years | 13 (2-18) | 12 (2-18) | 11 (2-18) | 10 (2-18) | 10 (2-18) |
| Age groups | |||||
| 2-5 | 39 (14) | 80 (16) | 339 (18) | 115 (20) | 96 (22) |
| 6-9 | 55 (20) | 112 (22) | 450 (24) | 156 (27) | 120 (27) |
| 10-13 | 54 (19) | 111 (22) | 394 (21) | 124 (22) | 115 (26) |
| 14-18 | 134 (48) | 206 (40) | 697 (37) | 178 (31) | 112 (25) |
| Sex | |||||
| Male | 195 (69) | 319 (63) | 1067 (57) | 339 (59) | 286 (65) |
| Ethnicity/race | |||||
| White | 149 (53) | 329 (65) | 1321 (70) | 410 (72) | 314 (71) |
| African American | 9 (3) | 20 (4) | 83 (4) | 30 (5) | 28 (6) |
| Hispanic | 4 (1) | 11 (2) | 82 (4) | 37 (6) | 21 (5) |
| Asian | 33 (12) | 48 (9) | 151 (8) | 36 (6) | 21 (5) |
| Middle eastern | 65 (23) | 74 (15) | 141 (8) | 26 (5) | 23 (5) |
| Missing | 20 (7) | 26 (4) | 91 (4) | 31 (5) | 31 (6) |
| Patient region | |||||
| United States | 64 (23) | 174 (34) | 828 (44) | 309 (54) | 270 (61) |
| Canada | 6 (2) | 17 (3) | 85 (5) | 26 (5) | 20 (5) |
| Europe | 74 (26) | 126 (25) | 510 (27) | 127 (22) | 84 (19) |
| Asia | 32 (11) | 37 (7) | 112 (6) | 27 (5) | 16 (4) |
| Middle East | 73 (26) | 82 (16) | 136 (7) | 28 (5) | 17 (4) |
| Lansky score | |||||
| ≥90% | 233 (83) | 422 (83) | 1579 (84) | 490 (86) | 377 (85) |
| Disease and status | |||||
| AML CR1 | 82 (32) | 108 (24) | 419 (25) | 82 (16) | 56 (14) |
| AML CR2 | 21 (8) | 55 (12) | 168 (10) | 52 (10) | 39 (9) |
| MDS | 27 (10) | 62 (12) | 170 (9) | 51 (9) | 31 (7) |
| ALL CR1 | 48 (19) | 79 (18) | 265 (32) | 82 (16) | 56 (14) |
| ALL CR2 | 48 (19) | 115 (26) | 549 (32) | 230 (44) | 203 (49) |
| CML early | 39 (15) | 71 (16) | 248 (15) | 63 (12) | 48 (12) |
| CML inter/adv | 17 (7) | 18 (18) | 59 (3) | 12 (2) | 10 (1) |
| Time dx to BMT-n | |||||
| <12 months | 193 (68) | 305 (60) | 1051 (56) | 274 (48) | 179 (40) |
| >12 months | 88 (31) | 203 (40) | 829 (44) | 299 (52) | 264 (60) |
| HLA match/donor | |||||
| HLA Id siblings | 182 (65) | 269 (53) | 829 (44) | 241 (42) | 153 (35) |
| Other related patients | 24 (9) | 46 (9) | 158 (8) | 51 (9) | 43 (10) |
| URD well matched | 16 (6) | 44 (9) | 187 (10) | 78 (14) | 70 (16) |
| URD partially matched | 45 (16) | 111 (22) | 541 (29) | 153 (27) | 120 (27) |
| URD mismatched | 15 (5) | 39 (8) | 165 (9) | 50 (9) | 57 (13) |
| Conditioning | |||||
| CY +TBI+/−others | 158 (6) | 308 (12) | 992 (40) | 704 (28) | 331 (13) |
| BU + CY+/−others | 124 (10) | 201 (17) | 475 (40) | 282 (24) | 112 (9) |
| ATG or Campath | |||||
| ATG | 13 (5) | 32 (6) | 130 (7) | 45 (8) | 39 (9) |
| Campath | 4 (1) | 9 (2) | 42 (2) | 16 (3) | 6 (1) |
| TNC/kg- median 3 × 108/kg | |||||
| <3 | 129 (46) | 225 (44) | 877 (47) | 308 (54) | 251 (57) |
| >3 | 136 (48) | 249 (49) | 854 (45) | 239 (42) | 171 (39) |
| Unknown | 17 (6) | 35 (7) | 149 (8) | 26 (5) | 21 (5) |
| GVHD prophylaxis | |||||
| CSA + MTX+/− other | 203 (72) | 371 (73) | 1312 (70) | 404 (71) | 292 (66) |
| CSA only | 31 (11) | 54 (11) | 162 (9) | 51 (9) | 38 (9) |
| T depletion | 48 (17) | 84 (17) | 406 (22) | 118 (21) | 113 (26) |
| Year of transplant | |||||
| 1990-1998 | 190 (67) | 327 (65) | 1250 (66) | 335 (58) | 273 (61) |
| 1999-2007 | 92 (33) | 182 (35) | 630 (34) | 238 (42) | 170 (39) |
| Follow-up | |||||
| Median, range, months | 99 (3-221) | 87 (3-222) | 85 (3-229) | 80 (3-220) | 86 (3-201) |
BU, busulfan; CML, chronic myeloid leukemia; CR, complete remission; CSA, cyclosporine A; MDS, myelodysplastic syndrome; MSD, match sibling donor; MTX, methotrexate; RD, related donor; URD, unrelated donor; TNC, total nucleated cell dose.